Inclusion Criteria:

- Dose escalation cohort for all solid tumors is complete and closed to enrollment. For
the expansion cohorts, patients must have: advanced, inoperable differentiated
thyroid cancer (DTC), soft-tissue sarcoma or cholangiocarcinoma. Patients in the DTC
cohort must have disease that is able to be biopsied.

- Must have measurable disease.

- Tumor progression in the 6-month period prior to study drug initiation.

- DTC patients: must have radioiodine non-avid lesions, OR radioiodine avid lesions
that have not responded to treatment with radioactive iodine.

- ECOG performance status less than or equal to 1.

- Life expectancy >3 months.

- Blood pressure <140 mmHg and <90 mmHg.

- LVEF is >= 50%

- Must be able to swallow pills.

Exclusion Criteria:

- Chemotherapy, radiotherapy, other investigational therapy, or major surgery within 4
weeks.

- Sarcoma and cholangiocarcinoma ONLY: Prior VEGF-targeted TKI therapy.

- Pregnant or currently breastfeeding.

- Unresolved toxicity greater than grade 1.

- Evidence of active hepatitis or HIV.

- Significant cardiovascular disease.

- Taking medications known to be strong inducers or inhibitors of CYP3A enzymes.

- Clinically significant gastrointestinal abnormalities that may increase the risk for
gastrointestinal bleeding.

- History of gastrointestinal condition causing malabsorption or obstruction.

- Cerebrovascular accident including transient ischemic attack (TIA), pulmonary
embolism or untreated deep vein thrombosis (DVT) within past 6 months.

- Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that
increase risk of pulmonary hemorrhage.

- Hemoptysis within 6 months of starting treatment.

- History of retinal vein occlusion (RVO) or central serous retinopathy (CSR), or
predisposing factors to RVO or CSR as assessed by ophthalmic exam.

- Known brain mets that are not stable for at least 8 weeks prior to treatment, or
patient is on glucocorticoids for brain mets.